Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Abstract Objectives Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms...

Olles dieđut

Bibliográfalaš dieđut
Váldodahkkit: Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang
Materiálatiipa: Artihkal
Giella:English
Almmustuhtton: Wiley 2019-10-01
Ráidu:Cancer Medicine
Fáttát:
anaplastic lymphoma kinase inhibitor
crizotinib
crizotinib continuation beyond progressive disease
non‐small cell lung cancer
treatment duration
Liŋkkat:https://doi.org/10.1002/cam4.2420

Interneahtta

https://doi.org/10.1002/cam4.2420

Geahča maid